人白介素12亚基p40和p35基因串联在毕赤酵母中的表达及表达产物活性分析

摘 要 利用毕赤酵母系统表达有活性的人单链白细胞介素12（hscIL-12）,PCR法从质粒pBI121-IL-12中扩增hscIL-12基因,经酶切、连接构建重组表达载体pPIC9K-hscIL-12,SacI线性化后,PEG1000法转化毕赤酵母GS115,经G418筛选和菌落PCR鉴定,经甲醇诱导,hscIL-12在酵母中获得分泌表达,表达产物经Western Blot检测,显示该蛋白相对分子质量为70KDa,可与鼠抗人IL-12单克隆抗体特异性结合;定量分析结果表明,重组酵母培养上清中hscIL-12约占总蛋白的26％,表达量约为60mg／L;生物学活性实验表明,重组蛋白能促进人外周血淋巴细胞增殖。为利用rhscIL-12进行基因治疗奠定了基础。     

小鼠可溶性PD1的克隆、真核表达及生物学活性检测

旨在克隆小鼠PD1胞外区(简称mPD-1)基因,利用真核表达系统表达有活性的分泌型mPD-1蛋白,初步研究其生物学活性。克隆mPD-1基因,将其连入pcDNA3.1(+)/Fc中获得pcDNA3.1(+)-Fc/mPD-1重组表达质粒,转化至大肠杆菌DH5α,进行PCR和双酶切鉴定,并送测序。将阳性质粒转染L929细胞,利用RT-PCR和Western blotting方法鉴定mPD-1/L929稳定表达株。利用Alamar Blue法检测分泌的mPD-l蛋白对淋巴细胞增殖的影响,评价其生物学活性。结果显示,成功构建重组质粒pcDNA3.1(+)-Fc/mPD-1,转染了pcDNA3.1(+)-Fc/mPD-1的L929细胞可将mPD-l蛋白分泌至胞外。A lamar Blue检测结果显示,真核细胞分泌的mPD-1蛋白作用于混合淋巴细胞,与阴性对照相比,可明显促进淋巴细胞的增殖。本试验成功地克隆mPD-1胞外区蛋白,并在L929细胞中得到了分泌型表达。分泌的重组蛋白可有效促进淋巴细胞增殖,为进一步研究其功能和临床应用提供了条件。     

猪IL-18在毕赤酵母中的表达及活性分析

采用PCR方法从pGEM-IL-18重组质粒中扩增出IL-18基因并构建真核融合表达载体pPIC9K-IL-18,电激法转化入毕赤酵母GS115,采用G418抗性梯度法筛选得到多拷贝重组菌株,甲醇诱导表达,应用SDS-PAGE分析重组蛋白的表达情况,并将表达蛋白用凝胶层析柱纯化后,用MTT法检测其生物学活性。实验结果表明重组的GS115酵母菌株可表达分泌pIL-18,其表达在72h时达高峰,分泌量可达160mg/L,纯化的重组pIL-18蛋白具有显著的促进淋巴细胞增殖的活性,说明本试验已在毕赤酵母中在国内首次成功表达了具有生物学活性的pIL-18。     

Flt3配体胞外域的原核表达纯化及活性鉴定

目的:构建pET32a(+)-hFLext原核表达载体,诱导hFLext蛋白表达、纯化及活性鉴定.方法:以人淋巴细胞cDNA文库为模板,克隆hFlext,构建pET32a(+)-hFLext重组表达载体.转化大肠杆菌BL21,IPTG诱导蛋白表达,镍珠亲合层析纯化蛋白,SDS-PAGE及Western blot鉴定.细胞增殖实验检测其生物学活性.结果:成功克隆获得hFLext,并构建了pET32a(+)-hFLext重组表达载体.在大肠杆菌BL21,经1 mM IPTG 30℃诱导12 h,成功表达Trx-hFLext融合蛋白,主要以包涵体形式存在.经8M尿素变性包涵体蛋白,逐步透析复性,镍珠亲合层析纯化蛋白,SDS-PAGE及Western blot鉴定,成功获得高纯度的Trx-hFLext融合蛋白.细胞增殖实验证实其具有生物学活性,能够有效刺激脐血细胞增殖.结论:成功构建了pET32a(+)-hFLext重组表达载体,表达、纯化了具有生物学活性的Trx-hFLext融合蛋白,为造血干/祖细胞的体外扩增研究奠定了基础.     

马胎盘提取物对淋巴细胞的免疫调节作用

采用MTT法测定不同浓度马胎盘提取物(EPE)对正常、ConA和LPS诱导的小鼠脾淋巴细胞增殖活性以及NK细胞杀伤活性的影响;并用氨基酸自动分析仪检测马胎盘提取物中氨基酸的含量。MTT实验结果表明:马胎盘提取物(187.5～750μg/mL)明显增强正常淋巴细胞的活性;23.44～1500μg/mL明显抑制ConA诱导的T淋巴细胞增殖活性,750～1500μg/mL明显抑制LPS诱导的B淋巴细胞增殖活性,其对ConA诱导的T淋巴细胞增殖的抑制作用强于对LPS诱导的B淋巴细胞增殖的抑制作用;93.75～500μg/mL明显增强NK细胞对PC-3癌细胞的杀伤活性;氨基酸含量分析表明:其含有丰富的氨基酸,其中谷氨酸(7.53%)、天门冬氨酸(5.64%)和亮氨酸(5.54%)含量较高。因此马胎盘提取物对淋巴细胞可能具有一定的免疫调节作用。     

金黄色葡萄球菌类肠毒素K与GFP融合蛋白工程菌的构建及其表达蛋白生物学活性分析

目的:构建携带金黄色葡萄球菌类肠毒素K(staphylococcal enterotoxin-like K,SElK)和绿色荧光蛋白(green fluorescent protein,GFP)融合基因的工程菌,并对SElK-GFP融合蛋白进行初步生物学活性分析。方法:利用PCR和Overlap PCR克隆获得SElK-GFP融合基因,并插入pET28a表达载体中,通过菌落PCR,质粒双酶切及测序验证后,将构建成功的pET28a-SElK-GFP质粒转化到E. coli BL21菌株中进行诱导表达,通过Ni+亲和磁珠试剂盒纯化获得SElK-GFP融合蛋白;并利用MTT法检测SElK-GFP刺激小鼠脾淋巴细胞增殖; ELISA法检测SElK-GFP尾静脉注射后小鼠血清中细胞因子IL-2和IFN-γ的分泌水平。结果:成功构建能够表达SElK-GFP融合蛋白的工程菌,纯化获得高纯度的SElK-GFP融合蛋白可观测到明显的绿色荧光,融合蛋白生物学活性分析表明,SElK-GFP能够呈剂量依赖性地显著刺激小鼠脾淋巴细胞增殖;同时ELISA检测发现SElK-GFP可显著增加小鼠血清中细胞因子IL-2及IFN-γ的分泌水平。结论:成功克隆、表达及纯化获得高纯度的SElK-GFP融合蛋白,其不仅保留了SElK的超抗原活性,同时兼具GFP绿色荧光的可视性,为深入研究SElK生物学活性提供有利工具。     

胸腺素a1与复合a干扰素融合蛋白的表达及其生物学活性

实验旨在获得具有双重生物学活性的重组胸腺素a1(Thymosin alpha1, TM-a1)与复合a干扰素(IFNa-con)融合蛋白。选择大肠杆菌偏爱的密码子, 将合成的TM-a1与IFNa-con编码序列构成的融和基因克隆至大肠杆菌表达载体pET-22b(+)、在宿主菌BL21(DE3)-Codon plus-RP-X中成功表达了可溶性融合蛋白(TM-a1-IFN-con)。表达量占总蛋白的20%以上。通过硫酸铵沉淀、疏水层析、阴离子交换层析、阳离子交换层析、分子筛层析后, 产品纯度达到96%以上。采用细胞病变抑制法测定融合蛋白的抗病毒活性, 采用细胞增殖实验检测融合蛋白对小鼠脾淋巴细胞增殖的影响。结果表明, 融合蛋白的抗病毒活性优于市售的IFNa1b和IFNa2a。对小鼠脾淋巴细胞增殖的影响与市售的合成胸腺素a1相同。已有研究证实, 该融合蛋白具有良好的体外抗HBV作用, 其体外抗HBV活性比联合应用TM-a1和干扰素a强, 且细胞毒性明显低于联合应用TM-a1和干扰素a。以上结果表明, 通过大肠杆菌表达的可溶性融合蛋白(TM-a1- IFN-con), 既具有良好的干扰素a抗病毒作用, 也具有胸腺素a1促淋巴细胞增殖作用。     

胸腺素α1与复合α干扰素融合蛋白的表达及其生物学活性

实验旨在获得具有双重生物学活性的重组胸腺素α1(Thymosin alphal,TM-α1)与复合α干扰素(IFNα-con)融合蛋白.选择大肠杆菌偏爱的密码子.将合成的TM-α1与IFNα-con编码序列构成的融和基因克隆至大肠杆菌表达载体pET-22b( )、在宿主茵BL21(DE3)-Codon plus-RP-X中成功表达了可溶性融合蛋白(TM-α1.IFN-con).表达量占总蛋白的20%以上.通过硫酸铵沉淀、疏水层析,阴离子交换层析、阳离子交换层析,分子筛层析后,产品纯度达到96%以上.采用细胞病变抑制法测定融合蛋白的抗病毒活性,采用细胞增殖实验检测融合蛋白对小鼠脾淋巴细胞增殖的影响.结果表明.融合蛋白的抗病毒活性优于市售的IFNα1b和IFNα2a.对小鼠脾淋巴细胞增殖的影响与市售的合成胸腺素α1相同.已有研究证实.该融合蛋白具有良好的体外抗HBV作用.其体外抗HBV活性比联合应用TM-α1和干扰素α强,且细胞毒性明显低于联合应用TM-α1和干扰素α,以上结果表明,通过大肠杆菌表达的可溶性融合蛋白(TM-α1.IFN-con).既具有良好的干扰素α抗病毒作用.也具有胸腺素α1促淋巴细胞增殖作用.     

重组人可溶性B淋巴细胞刺激因子及其突变体的克隆、表达及活性测定

采用RT PCR方法从人外周血白细胞总RNA中钓取人可溶性B淋巴细胞刺激因子 (humansolubleBlym phocytestimulator,hsBLyS)的cDNA片段 ,再运用基因重组手段 ,利用通用型质粒pBV2 2 0构建表达载体pBV2 2 0 /hsBLyS。经测序鉴定后 ,以之为模板使用重叠PCR法扩增得到hsBLyS的两个点突变体hsBY A(Cys14 6→Ala14 6)和hsBY V (Cys14 6→Val14 6)的基因片段 ,构建表达载体 pBV2 2 0 /hsBY A及 pBV2 2 0 /hsBY V。经测序无误后 ,将上述 3种载体分别转化大肠杆菌DH5α并诱导重组蛋白质表达 ,薄层扫描结果显示 3种蛋白质在DH5α中表达量都在 2 0 %～ 30 %之间。再分别运用变性、凝胶过滤层析及复性等手段纯化目的蛋白质 ,最后通过B淋巴细胞增殖实验检测纯化产物促人B细胞增殖的活性。实验结果表明 ,3种重组蛋白质都能明显刺激人B细胞增殖 ;统计学检验显示 ,突变体rhsBY V较野生型rhsBLyS的促人B淋巴细胞增殖活性显著增强。     

抗果蝇MRJ蛋白单克隆抗体的制备和鉴定

制备抗果蝇MRJ蛋白单克隆抗体可用于研究果蝇mrj的生物学功能,使用IPTG诱导重组质粒pET28a-mrj在大肠杆菌Rosetta中表达,重组蛋白经过Ni-IDA凝胶柱亲和纯化后免疫BALB/c小鼠。然后取免疫好的小鼠的脾脏细胞与小鼠骨髓瘤细胞SP2/0融合,经克隆和筛选获得了能分泌抗果蝇MRJ蛋白单克隆抗体的杂交瘤细胞株。腹水制备后获得单克隆抗体,通过ELISA和Western Blot对所获得的抗体进行鉴定,结果表明所制备单克隆抗体能够特异性结合于原核及真核细胞表达的MRJ蛋白,可用于研究mrj基因的生物学功能。     

IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts.

IL-12, formerly known as cytotoxic lymphocyte maturation factor, is a cytokine that stimulates proliferation of PHA-activated human peripheral blood lymphoblasts and synergizes with low concentrations of IL-2 in the induction of lymphokine-activated killer cells. IL-12 is a 75-kDa heterodimer composed of disulfide-bonded 40-kDa and 35-kDa subunits. mAb prepared against a partially purified preparation of natural IL-12 have been characterized by 1) immunoprecipitation of 125I-labeled IL-12, 2) immunodepletion of IL-12 bioactivity, 3) Western blotting of IL-12, 4) inhibition of [125I]IL-12 binding to its cellular receptor, and 5) neutralization of IL-12 bioactivity. Twenty antibodies immunoprecipitate 125I-labeled IL-12 and immunodeplete IL-12 bioactivity as assessed in the T cell proliferation and lymphokine-activated killer cell induction assays. Western blot analysis demonstrated that each antibody binds to the 75-kDa heterodimer and to the 40-kDa subunit. An IL-12R-binding assay identified 12 individual antibodies that inhibited the binding of [125I]IL-12 to its cellular receptor. Two inhibitory antibodies, 4A1 and 7B2, were tested in the neutralization assay and found to block IL-12 bioactivity whereas one noninhibitory antibody, 8E3, was shown not to neutralize IL-12 bioactivity. Antibodies 4A1 and 8E3 can simultaneously bind to the 75-kDa heterodimer demonstrating that inhibitory and noninhibitory epitopes are spatially distinct on the 40-kDa protein. The ability of antibodies specific for the 40-kDa subunit of IL-12 to block receptor binding of [125I]IL-12 and to neutralize IL-12 bioactivity suggests that localized determinants on the 40-kDa subunit may be necessary for binding to the IL-12 cellular receptor.     

Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor).

IL-12 is a heterodimeric cytokine that was identified on the basis of its ability to synergize with IL-2 in the induction of cytotoxic effector cells and was originally called cytotoxic lymphocyte maturation factor (CLMF). IL-12 was also found to stimulate the proliferation of PHA-activated lymphoblasts which were greater than 90% CD3+ T cells. In this report we further characterize the effects of IL-12 on lymphocyte proliferation. Studies with purified subpopulations of PHA-activated lymphoblasts and with cloned lines of human T cells indicated that IL-12 caused the proliferation of activated T cells of both the CD4+ and CD8+ subsets. This effect of IL-12 was independent of IL-2 because it was not blocked by antibodies to either IL-2 or IL-2R. The maximum proliferation induced by IL-12 was 31 to 72% of the maximum caused by IL-2; however, IL-12 was active at a lower effective concentration (EC50 = 8.5 +/- 1.3 pM) than IL-2 (EC50 = 52 +/- 8 pM). Combination of suboptimal amounts of IL-12 and IL-2 resulted in additive proliferation, up to the maximum induced by IL-2 alone. IL-12 also caused the proliferation of lymphocytes activated by culture with IL-2 for 6 to 12 days. CD56+ NK cells were among the IL-12-responsive cells in the IL-2-activated lymphocyte population. Unlike IL-2 or IL-7, IL-12 caused little or no proliferation of resting peripheral blood mononuclear cells (PBMC). In this regard, IL-12 was similar to IL-4. However, IL-12 could enhance the proliferation of resting PBMC caused by suboptimal amounts of IL-2, whereas IL-4 inhibited IL-2-induced PBMC proliferation. Thus, IL-12 is a growth factor for activated human T cells and NK cells; however, its spectrum of lymphocyte growth-promoting properties is distinct from that of IL-2, IL-4, or IL-7.     

Hypoxia-Induced Changes in the Bioactivity of Cytotrophoblast-Derived Exosomes

Migration of extravillous trophoblasts (EVT) into decidua and myometrium is a critical process in the conversion of maternal spiral arterioles and establishing placenta perfusion. EVT migration is affected by cell-to-cell communication and oxygen tension. While the release of exosomes from placental cells has been identified as a significant pathway in materno-fetal communication, the role of placental-derived exosomes in placentation has yet to be established. The aim of this study was to establish the effect of oxygen tension on the release and bioactivity of cytotrophoblast (CT)-derived exosomes on EVT invasion and proliferation. CT were isolated from first trimester fetal tissue (n = 12) using a trypsin-deoxyribonuclease-dispase/Percoll method. CT were cultured under 8%, 3% or 1% O2 for 48 h. Exosomes from CT-conditioned media were isolated by differential and buoyant density centrifugation. The effect of oxygen tension on exosome release (µg exosomal protein/10⁶cells/48 h) and bioactivity were established. HTR-8/SVneo (EVT) were used as target cells to establish the effect (bioactivity) of exosomes on invasion and proliferation as assessed by real-time, live-cell imaging (Incucyte™). The release and bioactivity of CT-derived exosomes were inversely correlated with oxygen tension (p<0.001). Under low oxygen tensions (i.e. 1% O2), CT-derived exosomes promoted EVT invasion and proliferation. Proteomic analysis of exosomes identified oxygen-dependent changes in protein content. We propose that in response to changes in oxygen tension, CTs modify the bioactivity of exosomes, thereby, regulating EVT phenotype. Exosomal induction of EVT migration may represent a normal process of placentation and/or an adaptive response to placental hypoxia.     

分枝杆菌制剂对小鼠的免疫调节作用的初步研究

探讨不同分枝杆菌制剂对小鼠的免疫调节作用。将C57BL/6小鼠,随机分成4组分别注射生理盐水、微黄分枝杆菌、草分枝杆菌和田鼠分枝杆菌制剂,每隔2周免疫一次。免疫2次后,小鼠取脾淋巴细胞体外培养,分别以PPD、PPDB刺激,用MTT法检测T淋巴细胞增殖情况;用酶联免疫斑点法(Enzyme-Linked ImmunoSpot assay,ELISpot)检测脾细胞分泌IFN-γ情况,分析各分枝杆菌制剂对小鼠免疫应答的影响。结果显示,与对照组相比,微黄分枝杆菌制剂和草分枝杆菌制剂免疫小鼠的T淋巴细胞增殖反应和脾细胞分泌IFN-γ均明显提高,其中微黄分枝杆菌组与对照组相比有显著性差异(p<0.01)。分枝杆菌制剂可促进小鼠免疫应答。     

Anti-HLA class I antibodies inhibit the T cell-independent proliferation of human B lymphocytes

The role of major histocompatibility complex-encoded class I molecules in the proliferation of human B lymphocytes is presently unclear. This question was addressed by investigating the effect of three individually derived anti-HLA class I monoclonal antibodies (mAb) on purified human B cells (less than 1.5% T cells) stimulated by either the T-independent mitogen Staphylococcus aureus or the phorbol ester, phorbol-12-myristate-13-acetate. The three anti-HLA class I antibodies, whether specific for gene products of the HLA-A locus (mAb 131), HLA-B locus (mAb 4E), or HLA-A, -B, and -C locus (mAb W6/32), inhibited S. aureus-induced proliferation by 70 to 90%. This inhibition was significant over a 5-day culture period, was not altered by the addition of exogenous interleukin 2 or B cell growth factor, and was not due to nonspecific cytotoxicity. In addition, the inhibition of proliferation was unchanged when the mAb were added 12 hr after the initiation of culture. The proliferative response was not affected by either of the control antibodies OKB7 and R3-367. In contrast with S. aureus-stimulated B cells, phorbol-12-myristate-13-acetate-induced proliferation was resistant to the inhibitory activity of HLA class I-specific antibodies. These results suggest that HLA class I molecules are involved in human B lymphocyte proliferation and may regulate a critical event preceding the upregulation of protein kinase C activity.     

Antibodies against cortisol block suppressive effects of corticosteroids on lymphocytes in vitro.

Lymphocyte transformation assays were used to test the ability of antibodies against cortisol to reduce bioactivity of corticosteroids in vitro. Mononuclear cells were separated from whole bovine blood and cultured in the presence of PHA alone, PHA + steroid, PHA + steroid + anticortisol, or PHA + steroid + anti-bovine serum albumin. Tritiated thymidine uptake was determined for all groups during the last 24 hr of a 72-hr culture period by scintillation counting. Polyclonal anticortisol against cortisol-bovine serum albumin conjugated in the 21 position was more effective in blocking cortisol activity than monoclonal anticortisol built against conjugates in the 3 position. The steroids that suppressed PHA-induced lymphocyte proliferation in a concentration-dependent manner were: cortisol, corticosterone, dexamethasone, prednisolone, 11-deoxycortisol, and 11-deoxycorticosterone. Aldosterone, cortisone, cholesterol, estradiol, and progesterone did not exhibit concentration-dependent effects and, thus, were not considered suppressive. These concentration-independent steroids were also the least suppressive (with the exception of aldosterone). Anticortisol was able to reduce bioactivity of suppressive corticosteroids that had an 11-hydroxy group, suggesting the antibody was primarily made against this site. Anti-BSA was not effective in blocking corticosteroid activity, but it did enhance proliferation of lymphocytes if added in combination with weakly suppressive steroids. Anticortisol also had an enhancing effect when added with some weakly suppressive steroids. We conclude that antibodies against cortisol are capable of reducing bioactivity of steroids that strongly suppress lymphocyte proliferation. Additionally, the 11-hydroxy group may be an important antigenic determinant of steroid molecules.     

猪IL-18在乳酸乳球菌中的表达及其生物活性的检测

为了在乳酸乳球菌中分泌表达具有生物活性的猪IL-18蛋白,并检测其生物活性,故通过分离猪外周血单核淋巴细胞(PBMC),以其为模板,采用RT-PCR方法扩增猪白细胞介素18(pIL-18)基因,将目的基因与乳酸乳球菌表达载体pAMJ399进行连接,并电转化至乳酸乳球菌MG1363中,通过SDS-PAGE和Western blotting分析检测目的蛋白的表达,并通过脾淋巴细胞增殖试验和细胞病变抑制法对pIL-18的生物活性进行检测。Western blotting分析检测结果与生物活性检测结果显示,在重组菌pAMJ399-pIL18/MG1363的上清和菌体沉淀中19 kDa处均出现pIL-18的特异蛋白反应带,且分泌表达的pIL-18蛋白能明显促进猪脾淋巴细胞的增殖,并对病毒增殖有明显的抑制作用。以上结果表明pIL-18可在乳酸乳球菌分泌表达,且表达产物具有良好的生物活性。     

Comparative study of intracellular glutathione content in rat lymphocyte cultures treated with 2-mercaptoethanol and interleukin-2

The level of intracellular glutathione (GSH) in mitogen-stimulated mouse lymphocytes is increased in the presence of 2-mercaptoethanol (2-ME), an enhancer of lymphocyte activation and proliferation. Since proliferation of lymphocytes in response to mitogens involves direct activation by a mitogen followed by continued proliferation in response to interleukin-2 (IL-2), we have investigated the effect of 2-ME and exogenous IL-2 on the GSH content and cell proliferation of rat lymphocytes stimulated with phytohemagglutinin (PHA). PHA stimulation increased both GSH content and the magnitude of the proliferative response, as measured by thymidine incorporation into cellular DNA. However, incubation of stimulated lymphocytes with 2-ME or IL-2 for 72 hr produced a significant further elevation of GSH levels and thymidine incorporation. 2-ME also increased the GSH content in unstimulated cultures, but it had little effect on thymidine incorporation. IL-2 increased GSH content and decreased thymidine incorporation in unstimulated lymphocytes. Exposure of cells to DL-buthionine-(S,R)-sulfoximine (BSO), an inhibitor of GSH biosynthesis, significantly depleted GSH and lowered the proliferative response, suggesting a crucial role of de novo GSH synthesis for lymphocyte activation. The data suggest that both 2-ME and IL-2 promote lymphocyte proliferation, although the mechanisms by which intracellular GSH levels are increased by the agents are apparently different.Copies of articles are available through ISI Document Delivery Services c/o The Genuine Article, 3501 Market Street, Philadelphia, PA 19104.